Objective To investigate the effect of PEGylated interferon on the clinical prognosis and the level of inflammatory cytokines in patients with chronic hepatitis C in plateau area. Method A total of 110 patients with chronic hepatitis C in plateau area in our hospital from April 2014 to September 2015 were randomly divided into observation group and control group, 55 cases in each group. Both groups patients received routine improvement of liver function and oral administration of Ribavirin. Observation group patients were treated with subcutaneous injection of PEGylated interferon. Control group patients were treated with subcutaneous injection of ordinary interferon. After treatment, virological responses, serum levels of inflammatory cytokines and antibody levels were compared between the two groups, and the incidence of adverse reactions was compared between the two groups during treatment. Result The complete early virological response and sustained virological response rate of observation group were significantly higher than control group (P<0.05). After treatment, two groups of patients with interleukin (IL)-6, IL-10, tumor necrosis factor alpha, C reactive protein, alanine aminotransferase, aspartate aminotransferase and total bilirubin levels were significantly lower than those before treatment (P < 0.05), and the above indexes of observation group was significantly lower than control group (P < 0.05). After treatment, the levels of interferon-γ in the two groups were significantly higher than those before treatment (P<0.05), and the level of IFN-γ of observation group was significantly higher than control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion For the chronic hepatitis C patients in plateau area, the efficacy of PEGylated interferon are significantly better than conventional interferon, which can better regulate the immune function of patients, reduce the inflammatory reaction, improve the prognosis, and have better safety.%目的 探讨聚乙二醇干扰素对高原地区慢性丙型肝炎患者临床预后和炎性因子水平的影响.方法 采用随机数表法将本院2014年4月至2015年9月收治的高原地区慢性丙型肝炎患者110例分为观察组和对照组,每组各55例.两组患者均接受常规改善肝功能治疗并口服利巴韦林,观察组患者在此基础上皮下注射聚乙二醇干扰素,对照组患者皮下注射普通干扰素.治疗结束后,比较两组患者的病毒学反应、血清炎性因子水平、抗体水平及不良反应发生情况.结果 观察组完全早期病毒学应答及持续病毒学应答患者占比均显著高于对照组(P<0.05).治疗后,两组患者白介素(IL)-6、IL-10、肿瘤坏死因子-α、C反应蛋白、谷丙转氨酶、谷草转氨酶、总胆红素水平均显著低于治疗前(P<0.05),且观察组患者上述指标水平均显著低于对照组(P<0.05).治疗后两组患者γ干扰素(IFN-γ)水平均显著高于治疗前(P<0.05),且观察组患者IFN-γ水平显著高于对照组(P<0.05).两组患者不良反应发生率无显著差异(P>0.05).结论 对于高原地区慢性丙型肝炎患者,聚乙二醇干扰素的疗效明显优于普通干扰素,可以更好地调节患者的免疫功能,减轻炎性反应,改善患者预后,且具有较好的安全性.
展开▼
